Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs.
Head Neck
; 45(6): 1468-1475, 2023 06.
Article
em En
| MEDLINE
| ID: mdl-36976786
ABSTRACT
BACKGROUND:
The impact of monoclonal antibody therapy (mAB) for advanced head and neck cancer on end-of-life health care utilization and costs has yet to be adequately studied.METHODS:
Retrospective cohort study of patients aged 65 and over with a diagnosis of head and neck cancer between 2007 and 2017 within the SEER-Medicare registry assessing the impact of mAB therapy (i.e., cetuximab, nivolumab, or pembrolizumab) on end-of-life health care utilization (ED visits, inpatient admissions, ICU admissions, and hospice claims) and costs.RESULTS:
Of 12 544 patients with HNC, 270 (2.2%) utilized mAB therapy at the end-of-life period. On multivariable analyses adjusting for demographic and clinicopathologic characteristics, there was a significant association between mAB therapy and emergency department visits (OR 1.38, 95% CI 1.1-1.8, p = 0.01) and healthcare costs (ß $9760, 95% CI 5062-14 458, p < 0.01).CONCLUSIONS:
mAB use is associated with higher emergency department utilization and health care costs potentially due to infusion-related and drug toxicity expenses.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Assistência Terminal
/
Neoplasias de Cabeça e Pescoço
Tipo de estudo:
Health_economic_evaluation
/
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Head Neck
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos